61. Autoimmune hemolytic anemia Clinical trials / Disease details
Clinical trials : 146 / Drugs : 131 - (DrugBank : 59) / Drug target genes : 28 - Drug target pathways : 158
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05676697 (ClinicalTrials.gov) | January 13, 2023 | 7/12/2022 | PI3K Delta Inhibitor in Relapsed / Refractory Autoimmune Hemolytic Anemia Patients After Receiving Two or More Lines of Therapy | Safety and Efficacy Study of PI3K Delta Inhibitor in Relapsed / Refractory Autoimmune Hemolytic Anemia Patients After Receiving Two or More Lines of Therapy | Autoimmune Hemolytic Anemia;Failure of Two Rounds of Treatment | Drug: Linperlisib | Institute of Hematology & Blood Diseases Hospital | YL-Pharma | Recruiting | 18 Years | N/A | All | 20 | Phase 1 | China |